Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II trial assessing NRX-101 for the treatment of Suicidal Post-traumatic Stress Disorder (PTSD)

Next Previous
Search
Trial Profile

A phase II trial assessing NRX-101 for the treatment of Suicidal Post-traumatic Stress Disorder (PTSD)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cycloserine/lurasidone (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Therapeutic Use

    • Most Recent Events

    • 09 Jun 2023 According to a NRx Pharmaceuticals media release, the company has closed its previously announced registered direct offering for the purchase and sale of 9,670,002 shares of common stock at a purchase price of $0.65 per share of common stock and intends to use the net proceeds from the offering for working capital and general corporate purposes and may use the net proceeds to initiate research into the use of NRX-101 for the treatment of PTSD and Chronic Pain.
    • 16 May 2023 According to a NRx Pharmaceuticals media release, the study expected to be open for enrollment in 2023.
    • 30 Mar 2023 According to a NRx Pharmaceuticals media release, the Company expects to commence this study in 2Q 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top